Clinical TrialJul 13, 2026, 07:06 AM
Longeveron Laromestrocel Data Shows Brain Inflammation Stabilization in AD
AI Summary
Longeveron Inc. announced additional analysis from its Phase 2a clinical trial of laromestrocel for mild Alzheimer’s disease, presented at the 2026 Alzheimer’s Association International Conference. The data showed that laromestrocel stabilized brain inflammation in key gray and white matter regions, with reductions in free water correlating with improved clinical outcomes and anti-atrophic responses. Blood biomarker analysis also supported these findings. The company has received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its Alzheimer’s program and has aligned on a Phase 3 study design.
Key Highlights
- Laromestrocel data presented at 2026 AAIC showed stabilization of brain inflammation in AD patients.
- Results indicate a clinically relevant and durable anti-inflammatory mechanism of action.
- Reduction in free water detected by MRI correlated with improved clinical outcomes and anti-atrophic responses.
- Post-hoc analysis showed anti-inflammatory effect in hippocampus, temporal lobe, and AD-associated areas.
- Blood plasma analysis indicated reduced neurogranin and increased IL-13.
- U.S. FDA granted laromestrocel RMAT and Fast Track designations for Alzheimer's disease.
- Longeveron has aligned on a Phase 3 study design for laromestrocel in AD.
Price Impact
More from LGVN